The MI-CLAIM-GEN checklist for generative artificial intelligence in health. Read more about The MI-CLAIM-GEN checklist for generative artificial intelligence in health.
Author Correction: Genetically adjusted PSA levels for prostate cancer screening. Read more about Author Correction: Genetically adjusted PSA levels for prostate cancer screening.
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Read more about Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
Predatory journals: what can we do to protect their prey? Read more about Predatory journals: what can we do to protect their prey?
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Read more about Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Read more about Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Author Correction: Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Read more about Author Correction: Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation. Read more about Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation.
A prognostic neural epigenetic signature in high-grade glioma. Read more about A prognostic neural epigenetic signature in high-grade glioma.
Publisher Correction: Advancing T cell-based cancer therapy with single-cell technologies. Read more about Publisher Correction: Advancing T cell-based cancer therapy with single-cell technologies.
